142 related articles for article (PubMed ID: 35675794)
1. Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage.
Luettges K; Bode M; Diemer JN; Schwanbeck J; Wirth EK; Klopfleisch R; Kappert K; Thiele A; Ritter D; Foryst-Ludwig A; Kolkhof P; Wenzel UO; Kintscher U
Am J Nephrol; 2022; 53(7):552-564. PubMed ID: 35675794
[TBL] [Abstract][Full Text] [Related]
2. Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension.
Ling YH; Krishnan SM; Chan CT; Diep H; Ferens D; Chin-Dusting J; Kemp-Harper BK; Samuel CS; Hewitson TD; Latz E; Mansell A; Sobey CG; Drummond GR
Pharmacol Res; 2017 Feb; 116():77-86. PubMed ID: 27986554
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
4. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
[TBL] [Abstract][Full Text] [Related]
5. Sodium butyrate ameliorates deoxycorticosterone acetate/salt-induced hypertension and renal damage by inhibiting the MR/SGK1 pathway.
Wu C; Chen Z; Zhang L; Zhu Y; Deng M; Huang C; Liu Y; Zhu Q; Wang L
Hypertens Res; 2021 Feb; 44(2):168-178. PubMed ID: 32908237
[TBL] [Abstract][Full Text] [Related]
6. CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
Arai K; Morikawa Y; Ubukata N; Tsuruoka H; Homma T
J Pharmacol Exp Ther; 2016 Sep; 358(3):548-57. PubMed ID: 27384074
[TBL] [Abstract][Full Text] [Related]
7. IL-18 (Interleukin-18) Produced by Renal Tubular Epithelial Cells Promotes Renal Inflammation and Injury During Deoxycorticosterone/Salt-Induced Hypertension in Mice.
Thomas JM; Ling YH; Huuskes B; Jelinic M; Sharma P; Saini N; Ferens DM; Diep H; Krishnan SM; Kemp-Harper BK; O'Connor PM; Latz E; Arumugam TV; Guzik TJ; Hickey MJ; Mansell A; Sobey CG; Vinh A; Drummond GR
Hypertension; 2021 Nov; 78(5):1296-1309. PubMed ID: 34488433
[TBL] [Abstract][Full Text] [Related]
8. Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice.
Rhaleb NE; Pokharel S; Sharma U; Carretero OA
J Hypertens; 2011 Feb; 29(2):330-8. PubMed ID: 21052020
[TBL] [Abstract][Full Text] [Related]
9. Detrimental role of sphingosine kinase 1 in kidney damage in DOCA-salt hypertensive model: evidence from knockout mice.
Lyu B; Wang W; Ji XY; Ritter JK; Li N
BMC Nephrol; 2020 May; 21(1):173. PubMed ID: 32393187
[TBL] [Abstract][Full Text] [Related]
10. Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice.
Li Y; Chakraborty A; Broughton BRS; Ferens D; Widdop RE; Ricardo SD; Samuel CS
Biomed Pharmacother; 2021 Dec; 144():112256. PubMed ID: 34607108
[TBL] [Abstract][Full Text] [Related]
11. JMJD3 ablation in myeloid cells confers renoprotection in mice with DOCA/salt-induced hypertension.
Gao Y; Yu W; Song J; Nie J; Cui Z; Wen S; Liu B; Liang H
Hypertens Res; 2023 Aug; 46(8):1934-1948. PubMed ID: 37248323
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
[TBL] [Abstract][Full Text] [Related]
13. Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1K/DOCA/salt-induced hypertension.
Li Y; Shen M; Ferens D; Broughton BRS; Murthi P; Saini S; Widdop RE; Ricardo SD; Pinar AA; Samuel CS
Br J Pharmacol; 2021 Mar; 178(5):1164-1181. PubMed ID: 33450051
[TBL] [Abstract][Full Text] [Related]
14. Triptolide attenuates renal damage by limiting inflammatory responses in DOCA-salt hypertension.
Zhang J; Zhu M; Zhang S; Xie S; Gao Y; Wang Y
Int Immunopharmacol; 2020 Dec; 89(Pt A):107035. PubMed ID: 33045566
[TBL] [Abstract][Full Text] [Related]
15. The protective effect of Bergamot Polyphenolic Fraction on reno-cardiac damage induced by DOCA-salt and unilateral renal artery ligation in rats.
Carresi C; Cardamone A; Coppoletta AR; Caminiti R; Macrì R; Lorenzo F; Scarano F; Mollace R; Guarnieri L; Ruga S; Nucera S; Musolino V; Gliozzi M; Palma E; Muscoli C; Volterrani M; Mollace V
Biomed Pharmacother; 2024 Feb; 171():116082. PubMed ID: 38242036
[TBL] [Abstract][Full Text] [Related]
16. Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline α1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based α1-adrenoceptor antagonist.
Kubacka M; Zadrożna M; Nowak B; Kotańska M; Filipek B; Waszkielewicz AM; Marona H; Mogilski S
Hypertens Res; 2019 Aug; 42(8):1125-1141. PubMed ID: 30872813
[TBL] [Abstract][Full Text] [Related]
17. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.
Matsumura Y; Hashimoto N; Taira S; Kuro T; Kitano R; Ohkita M; Opgenorth TJ; Takaoka M
Hypertension; 1999 Feb; 33(2):759-65. PubMed ID: 10024341
[TBL] [Abstract][Full Text] [Related]
18. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension.
Ndisang JF; Jadhav A
J Pharmacol Exp Ther; 2010 Jul; 334(1):87-98. PubMed ID: 20392817
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.
Peng H; Carretero OA; Alfie ME; Masura JA; Rhaleb NE
Hypertension; 2001 Mar; 37(3):974-80. PubMed ID: 11244026
[TBL] [Abstract][Full Text] [Related]
20. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
Kolkhof P; Hartmann E; Freyberger A; Pavkovic M; Mathar I; Sandner P; Droebner K; Joseph A; Hüser J; Eitner F
Am J Nephrol; 2021; 52(8):642-652. PubMed ID: 34111864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
